120 related articles for article (PubMed ID: 18350301)
1. [Topical application of EGF for the therapy of persisting corneal erosion under cetuximab treatment].
Förster CG; Cursiefen C; Kruse FE
Ophthalmologe; 2008 Mar; 105(3):269-73. PubMed ID: 18350301
[TBL] [Abstract][Full Text] [Related]
2. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody).
Foerster CG; Cursiefen C; Kruse FE
Cornea; 2008 Jun; 27(5):612-4. PubMed ID: 18520515
[TBL] [Abstract][Full Text] [Related]
3. Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea.
Moon HS; Li L; Yoon HJ; Ji YS; Yoon KC
BMC Ophthalmol; 2020 Apr; 20(1):147. PubMed ID: 32295556
[TBL] [Abstract][Full Text] [Related]
4. Controlled-release of epidermal growth factor from cationized gelatin hydrogel enhances corneal epithelial wound healing.
Hori K; Sotozono C; Hamuro J; Yamasaki K; Kimura Y; Ozeki M; Tabata Y; Kinoshita S
J Control Release; 2007 Apr; 118(2):169-76. PubMed ID: 17289206
[TBL] [Abstract][Full Text] [Related]
5. Effect of topical administration of epidermal growth factor on healing of corneal epithelial defects in horses.
Burling K; Seguin MA; Marsh P; Brinkman K; Madigan J; Thurmond M; Moon-Massat P; Mannis M; Murphy CJ
Am J Vet Res; 2000 Sep; 61(9):1150-5. PubMed ID: 10976751
[TBL] [Abstract][Full Text] [Related]
6. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.
Shin E; Lim DH; Han J; Nam DH; Park K; Ahn MJ; Kang WK; Lee J; Ahn JS; Lee SH; Sun JM; Jung HA; Chung TY
BMC Ophthalmol; 2020 Jan; 20(1):19. PubMed ID: 31918686
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Stimulates Transforming Growth Factor-Beta Receptor Type II Expression In Corneal Epithelial Cells.
Shu DY; Hutcheon AEK; Zieske JD; Guo X
Sci Rep; 2019 May; 9(1):8079. PubMed ID: 31147562
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid promoting corneal epithelial wound healing by transactivation of epidermal growth factor receptor.
Xu KP; Yin J; Yu FS
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):636-43. PubMed ID: 17251460
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.
Hoffmann S; Burchert A; Wunderlich A; Wang Y; Lingelbach S; Hofbauer LC; Rothmund M; Zielke A
Endocrine; 2007 Apr; 31(2):105-13. PubMed ID: 17873319
[TBL] [Abstract][Full Text] [Related]
10. Wound-induced HB-EGF ectodomain shedding and EGFR activation in corneal epithelial cells.
Xu KP; Ding Y; Ling J; Dong Z; Yu FS
Invest Ophthalmol Vis Sci; 2004 Mar; 45(3):813-20. PubMed ID: 14985295
[TBL] [Abstract][Full Text] [Related]
11. Expression of phosphatidylinositol 3-kinase during EGF-stimulated wound repair in rabbit corneal epithelium.
Zhang Y; Liou GI; Gulati AK; Akhtar RA
Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2819-26. PubMed ID: 10549641
[TBL] [Abstract][Full Text] [Related]
12. Lidocaine inhibits tyrosine kinase activity of the epidermal growth factor receptor and suppresses proliferation of corneal epithelial cells.
Hirata M; Sakaguchi M; Mochida C; Sotozono C; Kageyama K; Kuroda Y; Hirose M
Anesthesiology; 2004 May; 100(5):1206-10. PubMed ID: 15114219
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
14. Optimal concentration of human epidermal growth factor (hEGF) for epithelial healing in experimental corneal alkali wounds.
Kim MJ; Jun RM; Kim WK; Hann HJ; Chong YH; Park HY; Chung JH
Curr Eye Res; 2001 Apr; 22(4):272-9. PubMed ID: 11462166
[TBL] [Abstract][Full Text] [Related]
15. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J
Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398
[No Abstract] [Full Text] [Related]
16. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
17. Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition.
Rush JS; Bingaman DP; Chaney PG; Wax MB; Ceresa BP
Invest Ophthalmol Vis Sci; 2016 Nov; 57(14):5864-5871. PubMed ID: 27802516
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species (ROS) are essential mediators in epidermal growth factor (EGF)-stimulated corneal epithelial cell proliferation, adhesion, migration, and wound healing.
Huo Y; Qiu WY; Pan Q; Yao YF; Xing K; Lou MF
Exp Eye Res; 2009 Dec; 89(6):876-86. PubMed ID: 19635476
[TBL] [Abstract][Full Text] [Related]
19. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
20. Treatment of corneal defects with delayed re-epithelization with a medical device/drug delivery system for epidermal growth factor.
Holland S; Morck D; Schultz C
Clin Exp Ophthalmol; 2012; 40(7):662-8. PubMed ID: 22429860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
